The Automation Partnership to Manufacture Cellectricon's Ion Channel Screening Platform | GenomeWeb
NEW YORK (GenomeWeb News) – Cellectricon said today that the Automation Partnership will co-develop and manufacture Cellectricon’s DynaflowHT System, a high-throughput ion channel screening platform that the company plans to launch next year.
Cellectricon has been developing the Dynaflow HT platform, a cell-based microfluidics electrophysiology system, over the last three years in partnership with AstraZeneca.
Financial terms of the agreement with TAP were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.